TREATMENT AND PREVENTION OF ADRENOCORTICAL CARCINOMA

• US 20170088836A1
• Filed: 09/23/2016
• Published: 03/30/2017
• Est. Priority Date: 09/25/2015
• Status: Abandoned Application

• Current Assignee: Anthony Glover, Bruce Robinson, Jing Ting Zhao, Stanley Sidhu
• Original Assignee: Anthony Glover, Bruce Robinson, Jing Ting Zhao, Stanley Sidhu
• Inventors: Glover, Anthony, Zhao, Jing Ting, Robinson, Bruce, Sidhu, Stanley
• Application Number:
  US15/274,961
• Publication Number:
  US 20170088836A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/141 MicroRNAs, miRNAs

Abstract

The invention relates to compositions and methods utilising miR-7 microRNA

Claims

1. A method of treating adrenocortical carcinoma (ACC) in an individual, the method including providing a therapeutically effective amount of a miR-7 microRNA in the individual, thereby treating ACC in the individual.

2. The method according to claim 1 wherein the miR-7 microRNA is provided in an ACC cell of the individual.

3. The method according to claim 2 wherein the amount of miR-7 microRNA provided in the ACC cell is at least the same as the amount of miR-7 microRNA in a non-cancerous adrenal cortex cell.

4. The method according to claim 1, wherein the miR-7 microRNA includes:

a) a first oligonucleotide of between 17-25 nucleotides having a sequence that is 80-100% identical to the nucleotide sequence of SEQ ID NO;

2

b) a second oligonucleotide of between 17-25 nucleotides having a sequence that is 60-100% identical to the sequence complementary to the nucleotide sequence of SEQ ID NO;

2.

5. The method according to claim 1 wherein the miR-7 microRNA includes a chemical modification.

6. The method according to claim 1, wherein miR-7 microRNA is provided in the individual by administering a nucleic acid construct to the individual for formation of miR-7 microRNA in the individual.

7. The method according to claim 6 wherein the nucleic acid construct includes:

a coding region for encoding a double stranded RNA molecule;

a promoter operable in a cell for the production of a double stranded RNA molecule;

wherein the double stranded RNA molecule has a sequence that enables the production of a miR-7 microRNA.

8. The method according to claim 1 wherein the method further includes simultaneous or co-administration of a further anti-cancer therapy.

9. An anti-cancer agent in the form of a nanoparticle containing a nucleic acid construct, wherein the nucleic acid construct includes:

a coding region for encoding a double stranded RNA molecule;

a promoter operable in a cell for the production of a double stranded RNA molecule;

wherein the double stranded RNA molecule has a sequence that enables the production of a miR-7 microRNA.

10. An anti-cancer agent in the form of a nanoparticle having an miR-7 microRNA attached thereto.

11. The anti-cancer agent according to claim 10, wherein the miR-7 microRNA is contained within the nanoparticle.

12. The agent according to claim 11, wherein the nanoparticle is derived from a bacterium.

13. The anti-cancer agent according to claim 12, wherein the miR-7 microRNA includes a nucleotide sequence that is at least 80% identical to the nucleotide sequence of SEQ ID NO:

2.

14. The anti-cancer agent according to claim 13 wherein the miR-7 microRNA includes:

a) a first oligonucleotide of between 17-25 nucleotides having a sequence that is between 80% to 100% identical to the nucleotide sequence of SEQ ID NO;

2;

b) a second oligonucleotide of between 17-25 nucleotides having a sequence that is between 60% to 100% identical to the nucleic acid sequence complementary to the nucleotide sequence of SEQ ID NO;

2.

15. The anti-cancer agent according to claim 14, wherein the miR-7 microRNA further comprises a chemical modification.

16. A pharmaceutical composition including the agent of claim 15.

17. The agent according to claim 10, wherein the nanoparticle comprises an antibody for targeting the miR-7 microRNA to a cell or tissue to which the miR-7 microRNA is to be provided.

18. Use of an anti-cancer agent according to claim 10 in the manufacture of a medicament for treating cancer in an individual.

19. The use according to claim 18 wherein the cancer is an adrenocortical carcinoma.